Effect of Graphic Warning Labels on Cigarette Pack-Hiding Behavior Among Smokers: The CASA Randomized Clinical Trial.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 06 2022
Historique:
entrez: 2 6 2022
pubmed: 3 6 2022
medline: 7 6 2022
Statut: epublish

Résumé

The inclusion of graphic warning labels (GWLs) on cigarette packs is recommended for tobacco control but has not yet been implemented in the US. It is unknown whether and to what extent the inclusion of GWLs on cigarette packs affects smokers' willingness to display the packs in public. To determine whether the inclusion of GWLs on cigarette packs affects pack-hiding behavior among smokers in social settings. This community-based randomized clinical trial assessed smokers' real-world experience of using cigarettes repackaged to include GWLs (GWL packs) compared with standard US packs and blank packs over a 3-month intervention period with 12 months of follow-up between September 6, 2016, and December 3, 2019. The study included 357 participants aged 21 to 65 years from San Diego County, California, who smoked 5 or more cigarettes per day, were not actively planning to quit smoking, were not pregnant, and had no unstable medical conditions. Participants purchased and received cigarette packs through the study website. During the 1-month run-in period, participants received their usual US cigarette packs. During the 3-month intervention period, participants were randomized to receive GWL packs (study-manufactured packs with 3 rotating images under license from the Commonwealth of Australia; GWL pack group), blank packs (study-manufactured packs devoid of industry marketing imagery; blank pack group), or standard US packs (US pack group). Pack hiding was queried daily (with participants reporting behavior within the last 4 hours) and weekly via interactive text messages during the 1-month run-in and intervention periods. Self-reported smoking behavior was biochemically validated. Among 357 enrolled participants, the mean (SD) age was 39.3 (11.8) years; 195 participants (54.6%) were female, 40 (11.2%) were Hispanic, 243 (68.1%) were non-Hispanic White, and 74 (20.7%) were of other non-Hispanic races (including American Indian or Alaska Native, Asian or Pacific Islander, Black or African American, or multiracial). A total of 18 987 cigarette packs were purchased and delivered during the run-in and intervention periods. Daily querying showed that the inclusion of GWLs on cigarette packs increased the percentage of smokers who hid their packs at least some of the time from 41.3% (95% CI, 39.6%-43.0%) during the run-in period to 57.1% (95% CI, 55.9%-58.1%) by the end of the intervention period. In the postintervention period, returning to standard US packs reduced pack-hiding behavior to the levels observed during the run-in period. Pack hiding remained at run-in levels for both the blank pack group (35.2%; 95% CI, 33.6%-36.8%) and the US pack group (41.4%; 95% CI, 39.7%-43.1%]) throughout the study. Although even participants in the GWL group with the lowest prestudy tendency to conceal score (ie, 1) had a mean (SE) probability of pack hiding during the intervention of 0.84 (0.02), this group's probability of pack hiding decreased to a mean (SE) of 0.43 (0.03) after intervention. When social reactions to packs were queried at the end of the study, the modal response from participants in the GWL pack group was observers' aversive reactions to the packs, whereas the modal response from participants in the blank pack group was observers' positive interest in the study. Neither smoking prevalence nor consumption differed by group at any point in the study. In this randomized clinical trial, receiving cigarettes in GWL packs vs blank packs increased pack-hiding behavior in social settings, which may be associated with aversive reactions from observers. However, 12-month smoking behavior did not change. ClinicalTrials.gov Identifier: NCT02676193.

Identifiants

pubmed: 35653155
pii: 2792860
doi: 10.1001/jamanetworkopen.2022.14242
pmc: PMC9164006
doi:

Banques de données

ClinicalTrials.gov
['NCT02676193']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2214242

Subventions

Organisme : NCI NIH HHS
ID : R01 CA190347
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA234539
Pays : United States

Références

JAMA Netw Open. 2021 Aug 2;4(8):e2121387
pubmed: 34347057
Am J Public Health. 2012 Feb;102(2):343-51
pubmed: 22390449
Tob Control. 2019 Aug;28(e1):e31-e36
pubmed: 30409812
Soc Sci Med. 2015 Nov;145:26-34
pubmed: 26439764
Science. 2016 Oct 7;354(6308):42-43
pubmed: 27846488
Tob Control. 2021 Sep 12;:
pubmed: 34511408
Control Clin Trials. 1988 Dec;9(4):345-64
pubmed: 3203525
Contemp Clin Trials. 2020 Nov;98:106152
pubmed: 32966877
Br J Addict. 1991 Sep;86(9):1119-27
pubmed: 1932883
Cancer Prev Res (Phila). 2019 Jan;12(1):3-12
pubmed: 30305281
Sci Rep. 2020 Jun 26;10(1):10487
pubmed: 32591555
Soc Sci Med. 2021 Jul;280:113983
pubmed: 34020313
Eur J Public Health. 2018 Aug 1;28(4):702-707
pubmed: 29596579
BMJ Open. 2019 Sep 6;9(9):e027868
pubmed: 31494599
Cochrane Database Syst Rev. 2017 Apr 27;4:CD011244
pubmed: 28447363
Appetite. 2016 Apr 1;99:219-234
pubmed: 26785316
PLoS One. 2018 Dec 12;13(12):e0208950
pubmed: 30540825
Tob Control. 2022 Mar 1;:
pubmed: 35232793
Addiction. 2012 Jun;107(6):1159-67
pubmed: 22372966
Prev Med. 1992 Nov;21(6):701-9
pubmed: 1438116
Soc Sci Med. 2015 Jan;124:187-95
pubmed: 25461876
Ann Intern Med. 2010 Jun 1;152(11):726-32
pubmed: 20335313

Auteurs

John P Pierce (JP)

Cancer Control Program, Moores Cancer Center, University of California, San Diego, La Jolla.
Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, San Diego.

Sheila Kealey (S)

Cancer Control Program, Moores Cancer Center, University of California, San Diego, La Jolla.

Eric C Leas (EC)

Cancer Control Program, Moores Cancer Center, University of California, San Diego, La Jolla.
Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, San Diego.

Kim Pulvers (K)

Department of Psychology, California State University, San Marcos.

Matthew D Stone (MD)

Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, San Diego.

Jesica Oratowski (J)

Cancer Control Program, Moores Cancer Center, University of California, San Diego, La Jolla.

Elizabeth Brighton (E)

Cancer Control Program, Moores Cancer Center, University of California, San Diego, La Jolla.

Adriana Villaseñor (A)

Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, San Diego.
Department of Epidemiology, Public Health Services, San Diego County, San Diego, California.

David R Strong (DR)

Cancer Control Program, Moores Cancer Center, University of California, San Diego, La Jolla.
Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, San Diego.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH